Evidence map›Paper›PMID 42811087›Full record

ReviewNature reviews. Nephrology2026

Metabolic control by liver-kidney crosstalk and glucagon in health and disease.

Volker Vallon, Nicolai J Wewer Albrechtsen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Volker VallonDepartments of Medicine and Pharmacology, University of California San Diego, La Jolla, CA, USA. vvallon@ucsd.edu.ORCID http://orcid.org/0000-0002-9211-2063
Nicolai J Wewer AlbrechtsenDepartment of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg, Copenhagen, Denmark. nicolai.albrechtsen@regionh.dk.ORCID http://orcid.org/0000-0003-4230-5753

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gluconeogenesis, nitrogen metabolism and acid-base regulation are fundamental for the maintenance of metabolic homeostasis. These three processes form an interconnected triangle, with liver-kidney crosstalk and the hormone glucagon at its core. Both kidney and liver perform gluconeogenesis, and they function in co-ordination to regulate the formation and excretion of the organic osmolyte urea and the acid equivalent ammonium, and to determine the usage and de novo generation of bicarbonate. Within the liver, glucagon promotes fasting-induced gluconeogenesis and the bicarbonate-consuming formation of urea from amino acid-derived ammonia in response to protein intake and catabolic states. Within the kidney, glucagon facilitates the excretion of urea. In metabolic acidosis, the liver shifts nitrogen metabolism from ureagenesis to glutamine formation for kidney ammoniagenesis. Liver and kidney disease interfere with whole-body homeostasis of glucose, nitrogen and acid-base by promoting hypo- or hyperglycaemia, ammonia and urea toxicity, and metabolic alkalosis or acidosis. Inhibitors of the sodium glucose cotransporter SGLT2 not only cause glucosuria and compensatory hepatic gluconeogenesis but also interfere with kidney bicarbonate reabsorption, leading to compensatory kidney ammoniagenesis, bicarbonate formation and gluconeogenesis, which mitigates lactate accumulation and is associated with improved kidney health. Glucagon receptor agonists, in combination with GLP1 receptor agonists, also hold therapeutic promise in obesity and fatty liver and potentially kidney disease, but a better understanding of their effects is needed in the pathophysiological setting.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.